Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice
Tóm tắt
Acute kidney injury following surgery incurs significant mortality with no proven preventative therapy. We investigated whether the α2 adrenoceptor agonist dexmedetomidine (Dex) provides protection against ischemia-reperfusion induced kidney injury in vitro and in vivo. In vitro, a stabilised cell line of human kidney proximal tubular cells (HK2) was exposed to culture medium deprived of oxygen and glucose. Dex decreased HK2 cell death in a dose-dependent manner, an effect attenuated by the α2 adrenoceptor antagonist atipamezole, and likely transduced by phosphatidylinositol 3-kinase (PI3K-Akt) signaling. In vivo C57BL/6J mice received Dex (25 μg/kg, intraperitoneal (i.p.)) 30 minutes before or after either bilateral renal pedicle clamping for 25 minutes or right renal pedicle clamping for 40 minutes and left nephrectomy. Pre- or post-treatment with Dex provided cytoprotection, improved tubular architecture and function following renal ischemia. Consistent with this cytoprotection, dexmedetomidine reduced plasma high-mobility group protein B1 (HMGB-1) elevation when given prior to or after kidney ischemia-reperfusion; pretreatment also decreased toll-like receptor 4 (TLR4) expression in tubular cells. Dex treatment provided long-term functional renoprotection, and even increased survival following nephrectomy. Our data suggest that Dex likely activates cell survival signal pAKT via α2 adrenoceptors to reduce cell death and HMGB1 release and subsequently inhibits TLR4 signaling to provide reno-protection.
Tài liệu tham khảo
Perico N, Cattaneo D, Sayegh MH, Remuzzi G: Delayed graft function in kidney transplantation. Lancet. 2004, 364: 1814-1827. 10.1016/S0140-6736(04)17406-0.
Stafford-Smith M, Shaw A, Swaminathan M: Cardiac surgery and acute kidney injury: emerging concepts. Curr Opin Crit Care. 2009, 15: 498-502. 10.1097/MCC.0b013e328332f753.
Koo DD, Welsh KI, Roake JA, Morris PJ, Fuggle SV: Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol. 1998, 153: 557-566. 10.1016/S0002-9440(10)65598-8.
Kashyap VS, Cambria RP, Davison JK, L'Italien GJ: Renal failure after thoracoabdominal aortic surgery. J Vasc Surg. 1997, 26: 949-955. 10.1016/S0741-5214(97)70006-5.
Kupiec-Weglinski JW, Busuttil RW: Ischemia and reperfusion injury in liver transplantation. Transplant Proc. 2005, 37: 1653-1656. 10.1016/j.transproceed.2005.03.134.
Sear JW: Kidney dysfunction in the postoperative period. Br J Anaesth. 2005, 95: 20-32. 10.1093/bja/aei018.
Borthwick E, Ferguson A: Perioperative acute kidney injury: risk factors, recognition, management, and outcomes. BMJ. 2010, 341: c3365-10.1136/bmj.c3365.
Englberger L, Suri RM, Greason KL, Burkhart HM, Sundt TM, Daly RC, Schaff HV: Deep hypothermic circulatory arrest is not a risk factor for acute kidney injury in thoracic aortic surgery. J Thorac Cardiovasc Surg. 2011, 141: 552-558. 10.1016/j.jtcvs.2010.02.045.
Cerda J, Lameire N, Eggers P, Pannu N, Uchino S, Wang H, Bagga A, Levin A: Epidemiology of acute kidney injury. Clin J Am Soc Nephrol. 2008, 3: 881-886. 10.2215/CJN.04961107.
Schrier RW, Wang W, Poole B, Mitra A: Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004, 114: 5-14.
Carden DL, Granger DN: Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000, 190: 255-266. 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6.
Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J: The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010, 6: 224-235. 10.1038/nrneph.2010.16.
Arslan F, Keogh B, McGuirk P, Parker AE: TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm. 2010, 2010: 704202-
Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005, 5: 331-342. 10.1038/nri1594.
Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006, 26: 174-179. 10.1097/01.shk.0000225404.51320.82.
Hoste EA, Kellum JA: Incidence, classification, and outcomes of acute kidney injury. Contrib Nephrol. 2007, 156: 32-38.
Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ: Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000, 90: 699-705. 10.1097/00000539-200003000-00035.
Sanders RD, Maze M: Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs. 2007, 8: 25-33.
Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M: Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004, 502: 87-97. 10.1016/j.ejphar.2004.08.044.
Kuhmonen J, Pokorny J, Miettinen R, Haapalinna A, Jolkkonen J, Riekkinen P, Sivenius J: Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology. 1997, 87: 371-377. 10.1097/00000542-199708000-00025.
Billings FTt, Chen SW, Kim M, Park SW, Song JH, Wang S, Herman J, D'Agati V, Lee HT: alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol. 2008, 295: F741-748. 10.1152/ajprenal.90244.2008.
Frumento RJ, Logginidou HG, Wahlander S, Wagener G, Playford HR, Sladen RN: Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery. J Clin Anesth. 2006, 18: 422-426. 10.1016/j.jclinane.2006.02.005.
Kulka PJ, Tryba M, Zenz M: Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med. 1996, 24: 947-952. 10.1097/00003246-199606000-00012.
Solez K, Ideura T, Silvia CB, Hamilton B, Saito H: Clonidine after renal ischemia to lessen acute renal failure and microvascular damage. Kidney Int. 1980, 18: 309-322. 10.1038/ki.1980.141.
Tsutsui H, Sugiura T, Hayashi K, Ohkita M, Takaoka M, Yukimura T, Matsumura Y: Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol. 2009, 603: 73-78. 10.1016/j.ejphar.2008.12.012.
Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D: Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med (Maywood). 235: 886-891.
Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, Sun P, Hossain M, Ma D, Maze M: Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology. 2009, 110: 1077-1085. 10.1097/ALN.0b013e31819daedd.
Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H, Hossain M, Maxwell PH, Maze M: Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol. 2009, 20: 713-720. 10.1681/ASN.2008070712.
Satake A, Takaoka M, Nishikawa M, Yuba M, Shibata Y, Okumura K, Kitano K, Tsutsui H, Fujii K, Kobuchi S, Ohkita M, Matsumura Y: Protective effect of 17beta-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway. Kidney Int. 2008, 73: 308-317. 10.1038/sj.ki.5002690.
Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB1: endogenous danger signaling. Mol Med. 2008, 14: 476-484.
Franks NP, Lieb WR: Volatile general anaesthetics activate a novel neuronal K+ current. Nature. 1988, 333: 662-664. 10.1038/333662a0.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005, 4: 988-1004. 10.1038/nrd1902.
Dahmani S, Rouelle D, Gressens P, Mantz J: Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology. 2005, 103: 969-977. 10.1097/00000542-200511000-00011.
Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E, Hutzler P, Kochs E: The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003, 96: 524-531.
O'Neill LA, Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007, 7: 353-364. 10.1038/nri2079.
Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001, 2: 675-680. 10.1038/90609.
Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ: TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007, 117: 2847-2859. 10.1172/JCI31008.
Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K: Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004, 32: 1322-1326. 10.1097/01.CCM.0000128579.84228.2A.
Venn RM, Bryant A, Hall GM, Grounds RM: Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth. 2001, 86: 650-656. 10.1093/bja/86.5.650.
Sanders RD, Hussell T, Maze M: Sedation & immunomodulation. Crit Care Clin. 2009, 25: 551-570. 10.1016/j.ccc.2009.05.001.
Memis D, Hekimoglu S, Vatan I, Yandim T, Yuksel M, Sut N: Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth. 2007, 98: 550-552. 10.1093/bja/aem017.
Gertler R, Brown HC, Mitchell DH, Silvius EN: Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001, 14: 13-21.
Philipp M, Brede M, Hein L: Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002, 283: R287-295.
Junaid A, Cui L, Penner SB, Smyth DD: Regulation of aquaporin-2 expression by the alpha(2)-adrenoceptor agonist clonidine in the rat. J Pharmacol Exp Ther. 1999, 291: 920-923.